Sequenom's iPLEX Gold Assay Receives Positive Feedback from Genomic Research Institutions
Complete the form below to unlock access to ALL audio articles.
Sequenom, Inc. has announced that its recently launched iPLEX™ Gold genotyping assay has been favorably received at The Broad Institute, a research collaboration of the Massachusetts Institute of Technology (MIT), Harvard and its affiliated hospitals, and the Whitehead Institute, and at Oxford University Medical Science Division's Wellcome Trust Centre for Human Genetics.
"We compared data from the new iPLEX Gold assay with the original iPLEX assay, and with iPLEX Gold have achieved a higher level of multiplexing and assay conversion, similar call rates, and nearly 100% concordance in genotype results," said Stacey Gabriel, Ph.D., Director, Genetic Analysis Platform for The Broad Institute.
"We are very pleased with the performance of Sequenom's new iPLEX Gold assay," said Jiannis Ragoussis, Ph.D., Head of Genomics of the Wellcome Trust Centre.
"We ran a significant number of assays using both methods and obtained the same high quality results, while achieving substantially increased levels of multiplexing with the iPLEX Gold assay."
According to the Company, its iPLEX Gold assay, the successor to the original iPLEX assay, reduces customer cost per data point to about 3 1/2 cents for typical fine mapping genotyping studies.
"Cost per data point is very important for fine mapping genotyping projects and our new iPLEX Gold assay was designed to meet the growing need for high value fine mapping genotyping solutions as researchers segue from whole genome studies into fine mapping," said Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom.
"It is important to our customers that we deliver the same high quality results they have been accustomed to with our original iPLEX assay at an even lower cost, and the feedback so far indicates that we are accomplishing this."
